Literature DB >> 15882113

Neurotensin agonists as an alternative to antipsychotics.

Mona Boules1, Paul Fredrickson, Elliott Richelson.   

Abstract

Neurotensin (NT) is a 13 amino acid neuropeptide that is found in the central nervous system and in the gastrointestinal tract. In brain, this peptide is prominently associated anatomically with dopaminergic, as well as other neurotransmitter systems. Based on animal studies, already decades old, researchers have hypothesised that NT receptor agonists will have antipsychotic properties in patients. However, to date no one has obtained a non-peptide NT receptor agonist. Therefore, there has been great interest in obtaining peptide analogues of NT, that, unlike NT resist degradation by peptidases and cross the blood-brain barrier, yet have the pharmacological characteristics of native NT, for therapeutic use in the treatment of schizophrenia, as well as other neuropsychiatric diseases such as Parkinson's disease and addiction to psychostimulants. In this review, we present the rationale for development of NT receptor agonists for treatment of certain central nervous system diseases, as well as a review of those peptide agonists that are in early stages of development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882113     DOI: 10.1517/13543784.14.4.359

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  14 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 2.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity.

Authors:  David Feifel; Zhen Pang; Zheng Pang; Paul D Shilling; Gilia Melendez; Rudy Schreiber; Donald Button
Journal:  Behav Brain Res       Date:  2010-04-21       Impact factor: 3.332

4.  The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature.

Authors:  David Feifel; Joseph Goldenberg; Gilia Melendez; Paul D Shilling
Journal:  Neuropharmacology       Date:  2009-07-09       Impact factor: 5.250

5.  The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance.

Authors:  David Feifel; Gilia Melendez; Rachel J Murray; Dan N Tina Tran; Michelle A Rullan; Paul D Shilling
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

6.  The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle.

Authors:  Paul D Shilling; David Feifel
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

7.  NT79: A novel neurotensin analog with selective behavioral effects.

Authors:  Mona Boules; Yanqi Liang; Siobhan Briody; Tomofumi Miura; Irfan Fauq; Alfredo Oliveros; Mina Wilson; Shaheen Khaniyev; Katrina Williams; Zhimin Li; Yanfei Qi; Michael Katovich; Elliott Richelson
Journal:  Brain Res       Date:  2009-10-27       Impact factor: 3.252

8.  Antipsychotic-induced gene regulation in multiple brain regions.

Authors:  Matthew James Girgenti; Laura K Nisenbaum; Franklin Bymaster; Rosemarie Terwilliger; Ronald S Duman; Samuel Sathyanesan Newton
Journal:  J Neurochem       Date:  2010-01-13       Impact factor: 5.372

9.  Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance.

Authors:  Siobhan Briody; Mona Boules; Alfredo Oliveros; Irfan Fauq; Elliott Richelson
Journal:  Behav Brain Res       Date:  2009-10-02       Impact factor: 3.332

Review 10.  Depression and antidepressants: molecular and cellular aspects.

Authors:  Cristina Lanni; Stefano Govoni; Adele Lucchelli; Cinzia Boselli
Journal:  Cell Mol Life Sci       Date:  2009-06-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.